Insider Transactions in Q1 2021 at Pfizer Inc (PFE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2021
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,855
-13.93%
|
$1,491,070
$34.07 P/Share
|
|
Feb 27
2021
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,925
+24.63%
|
$1,186,350
$22.35 P/Share
|
|
Feb 27
2021
|
William R Carapezzi Jr Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
16,661
-11.89%
|
$566,474
$34.07 P/Share
|
|
Feb 27
2021
|
William R Carapezzi Jr Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
21,570
+22.92%
|
$474,540
$22.35 P/Share
|
|
Feb 27
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,497
-16.51%
|
$254,898
$34.07 P/Share
|
|
Feb 27
2021
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
9,886
+29.4%
|
$217,492
$22.35 P/Share
|
|
Feb 27
2021
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
124,253
-10.6%
|
$4,224,602
$34.07 P/Share
|
|
Feb 27
2021
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
152,785
+20.1%
|
$3,361,270
$22.35 P/Share
|
|
Feb 27
2021
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
8,040
-12.25%
|
$273,360
$34.07 P/Share
|
|
Feb 27
2021
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
9,886
+22.42%
|
$217,492
$22.35 P/Share
|
|
Feb 27
2021
|
Alexander R Mackenzie Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
24,731
-8.31%
|
$840,854
$34.07 P/Share
|
|
Feb 27
2021
|
Alexander R Mackenzie Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
29,838
+16.29%
|
$656,436
$22.35 P/Share
|
|
Feb 27
2021
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
20,465
-11.15%
|
$695,810
$34.07 P/Share
|
|
Feb 27
2021
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
25,165
+20.89%
|
$553,630
$22.35 P/Share
|
|
Feb 27
2021
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
59,591
-16.32%
|
$2,026,094
$34.07 P/Share
|
|
Feb 27
2021
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
71,899
+27.09%
|
$1,581,778
$22.35 P/Share
|
|
Feb 27
2021
|
John D Young Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
105,251
-9.45%
|
$3,578,534
$34.07 P/Share
|
|
Feb 27
2021
|
John D Young Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
129,419
+18.37%
|
$2,847,218
$22.35 P/Share
|
|
Feb 27
2021
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
43,855
-15.38%
|
$1,491,070
$34.07 P/Share
|
|
Feb 27
2021
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
53,925
+26.42%
|
$1,186,350
$22.35 P/Share
|
|
Feb 27
2021
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
23,841
-14.76%
|
$786,753
$33.49 P/Share
|
|
Feb 25
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
9,571
-21.6%
|
$325,414
$34.29 P/Share
|
|
Feb 25
2021
|
Jennifer B. Damico SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,649
+13.48%
|
-
|
|
Feb 25
2021
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,477
+38.68%
|
$274,494
$22.89 P/Share
|
|
Feb 25
2021
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
133,928
-30.14%
|
$4,553,552
$34.29 P/Share
|
|
Feb 25
2021
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
163,334
+40.0%
|
$3,593,348
$22.86 P/Share
|
|
Feb 25
2021
|
William R Carapezzi Jr Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
20,601
-14.93%
|
$700,434
$34.29 P/Share
|
|
Feb 25
2021
|
William R Carapezzi Jr Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,222
+27.56%
|
$598,884
$22.89 P/Share
|
|
Feb 25
2021
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
133,928
-11.83%
|
$4,553,552
$34.29 P/Share
|
|
Feb 25
2021
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
163,334
+21.72%
|
$3,593,348
$22.89 P/Share
|
|
Feb 25
2021
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
18,602
-23.39%
|
$632,468
$34.29 P/Share
|
|
Feb 25
2021
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
22,686
+34.58%
|
$499,092
$22.89 P/Share
|
|
Feb 25
2021
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
28,271
-15.29%
|
$932,943
$33.82 P/Share
|
|
Feb 25
2021
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
30,793
-16.07%
|
$1,046,962
$34.29 P/Share
|
|
Feb 25
2021
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
37,658
+27.17%
|
$828,476
$22.89 P/Share
|
|
Feb 25
2021
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
81,845
-24.92%
|
$2,782,730
$34.29 P/Share
|
|
Feb 25
2021
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
99,816
+35.92%
|
$2,195,952
$22.89 P/Share
|
|
Feb 25
2021
|
Alexander R Mackenzie Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
14,227
-10.33%
|
$469,491
$33.82 P/Share
|
|
Feb 25
2021
|
Alexander R Mackenzie Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
26,732
+16.25%
|
-
|
|
Feb 25
2021
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,657
-17.46%
|
$260,338
$34.29 P/Share
|
|
Feb 25
2021
|
Payal Sahni Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
9,982
+30.31%
|
$219,604
$22.89 P/Share
|
|
Feb 25
2021
|
John D Young Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
133,928
-12.02%
|
$4,553,552
$34.29 P/Share
|
|
Feb 25
2021
|
John D Young Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
163,334
+21.98%
|
$3,593,348
$22.89 P/Share
|
|
Feb 25
2021
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
68,188
-19.19%
|
$2,318,392
$34.29 P/Share
|
|
Feb 25
2021
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
81,667
+30.09%
|
$1,796,674
$22.89 P/Share
|
|
Feb 22
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
884
-10.8%
|
$30,056
$34.26 P/Share
|
|
Feb 22
2021
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,172
-8.29%
|
$39,848
$34.26 P/Share
|
|
Feb 22
2021
|
William R Carapezzi Jr Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,410
-3.08%
|
$47,940
$34.26 P/Share
|
|
Jan 31
2021
|
Lidia Fonseca Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,749
-14.52%
|
$236,215
$35.9 P/Share
|